ArticleJournal of gastrointestinal oncology2023
Perioperative versus total neoadjuvant chemotherapy in gastric cancer.
Article in Journal of gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Tumor response to neoadjuvant treatment as a predictor of benefit for adjuvant treatment in esophago-gastric cancers: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Article
- Efficacy and safety of modified FLOT chemotherapy in gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study.Journal of gastrointestinal oncology · 2026Article
- Safety and feasibility of total neoadjuvant FLOT chemotherapy in locally-advanced gastric and gastroesophageal junction cancer.Oncology letters · 2026Article
- Perioperative chemotherapy (FLOT 4 + 4) versus total neoadjuvant therapy (TNT; FLOT ×8) for resectable gastric cancer: A systematic review and exploratory meta-analysis.Surgery open science · 2026Review
- Predicting the Unpredictable: Prognostic Role of Systemic Inflammatory Indices and Tumor Biology of Neoadjuvant Chemotherapy Response in Gastric and Gastroesophageal Junction Cancer-Insights from a Systematic Review and Real-World Experience.Journal of clinical medicine · 2026Article
- Gastric cancer and the TNT era: have we solved the timing question, or only redistributed the treatment?Frontiers in oncology · 2026Article
- Is More Really Better? Intensive Neoadjuvant Therapy and Standard Perioperative FLOT for Locally Advanced Gastric Cancer Demonstrate Similar Short-Term Outcomes.Annals of surgical oncology · 2025Article
- The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.Journal of surgical oncology · 2025Article
- Total Neoadjuvant Chemotherapy Followed by Laparoscopic Radical Gastrectomy Versus Neoadjuvant Chemotherapy for Clinical Stage T4a-bN + M0 Proximal Gastric Cancer: A Single-Center Retrospective Data Analysis.Gastroenterology research and practice · 2025Article
- Role of Preoperative Radiation Therapy for Resectable Gastric Cancer.Journal of gastrointestinal cancer · 2024Review
- Can the Pathological Response in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Treatment Be Predicted by the CEA/Albumin and CRP/Albumin Ratios?Journal of clinical medicine · 2024Article
- Development and validation of a nomogram to predict pathological complete response in patients with locally advanced gastric adenocarcinoma treated with neoadjuvant chemotherapy in combination with PD-1 antibodies.Journal of gastrointestinal oncology · 2023Article
- Reply to: Striking a balance: Deciphering the dilemma of treatment equivalence in cardia gastric cancer.Journal of surgical oncology · 2023Article
- Total neoadjuvant therapy for locally advanced gastric cancer: too much of a good thing?Journal of gastrointestinal oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
Background: Perioperative chemotherapy is standard of care management for locally advanced gastric cancer (GC), but a substantial proportion of patients do not complete adjuvant therapy due to postoperative complications and prolonged recovery. Administration of all chemotherapy prior to surgery in the form of total neoadjuvant therapy (TNT) may optimize complete delivery of systemic therapy. Methods: We performed a retrospective review of GC patients who had surgery at Memorial Sloan Kettering Cancer Center (MSKCC) from May 2014 to June 2020. Results: One hundred and forty-nine patients were identified; 121 patients received perioperative chemotherapy and 28 patients received TNT. TNT was chosen if patients had interim radiographic and/or clinical response to treatment. Baseline characteristics were well-balanced between the two group except for chemotherapy regimen; more TNT patients received FLOT compared to the perioperative group (79% Conclusions: Our study was limited by a small TNT sample size and biases inherent to a retrospective analysis. TNT appears to be feasible in a select population, without any increase in surgical morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.